For type 2 diabetes sotagliflozin 4 Phase III clinical lysanosis reached the main end point!

The company has released top-line data on the use of inhibitors in phase clinical studies of diabetes: Studies have reached the primary endpoint of lowering blood sugar levels in patientsThe safety in these studies is basically the same as that of approved inhibitorsDiarrhea A event consistent with gastrointestinal inhibition is usually more common in the group than in the placebo groupThe absolute increase in reproductive tract fungal infections with dose-related dose infections was higher than the higher dose of placebo than placeboThe incidence of hypoglycemia in one of the studies () was lower than in the other three studies, which were similar to placebosThe chemical structure is a two-acting inhibitor developed for use in andSanofi and The United States of China have a greed to acquire global rights other than JapanThe drug was rejected by the United States last month because of a higher incidence of ketoacidosis compared to placeboThe fact that EU regulators have recognized a common diabetes complication with a high incidence ratio has affirmed the positive benefit risk and approved the drug treatment last monthIn the same month, Sanofi announced the termination of the cooperationIt is worth noting that the success of the announcement project also states that it does not intend to seek regulatory approval for indications without a business partnerThe following results of the study: A randomized, double-blind, placebo-controlled study of patients who did not adequately control blood sugar levels through diet and exercise assessed the advantages of both doses () as compared to placebosThe results showed a significant lying decrease in the dose after treatment and placebo: A randomized, double-blind, placebo-controlled, parallel group study of patients treated with sulfomia or metformin but did not adequately control blood sugar levelsAssess the efficacy and safety of the dose combined with the placebo of sulfonate drugs (combined or not combined with metformin)Study the CPC Follow-up WeekThe results showed a significant reduction in levels and a decrease in levels up to the last day of treatment compared to placebos The average rate () of gloper filtration estimated in the first week was similar to that of placebo : A randomized, double-blind, double-simulated, positive drug and placebo-controlled, parallel group of patients treated with metformin but did not adequately control blood sugar levels The efficacy and safety of metformin were evaluated for dose, gremetlunos and placebo, respectively It is mainly to prove the non-poor effect of treatment week and Gremetinin in sugar reduction The results showed that the study reached the primary endpoint: the decrease in amount from baseline examination to the first week of treatment and the decrease in the Gremeilla group was the same : A randomized, double-blind, placebo-controlled study of patients who received basic insulin (combination or non-combination oral anti-sugar drugs) but did not adequately control blood sugar levels Assess the efficacy and safety of the seed dose () relative to the placebo The primary endpoint is the change in the baseline check through the first week The results showed that both doses significantly reduced the reduction and remained the same at the first week Reference source: